Jun 2026 (Q2 FY26) — Aug 11, 2026
NeurAxis Q2 FY26 — Strong Revenue Growth Driven by CPT Code and Payer Progress
Read the full callNeurAxis (NRXS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
NeurAxis earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1.9 | +115.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -110.2 | +82.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -2.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$7.85 +1.95% · +$0.15
Performance +159.1% 1Y
1Y: $3.03 on 17 Oct 2025 → $7.85. High $8.81 (6 May 2026), low $2.31 (17 Nov 2025).
- Previous close
- $7.7
- 52-week range
- $2.31 – $8.81
- One year
- +113.32%
Overview
- Symbol
- NRXS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
NeurAxis earnings calls (NRXS)
Financials
What the filings say
Net profit, year on year: −23% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Operating profit | -2 | -1 | -2 | -2 | -2 | -2 | -2 | -2 |
| Operating margin | −247.7% | −192.7% | −256.3% | −192.1% | −258.8% | −177.3% | −108.3% | −110.2% |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -2 | -1 | -2 | -2 | -2 | -2 | -2 | -2 |
| EPS ($ per share) | -0.25 | — | -0.33 | -0.22 | -0.24 | — | -0.18 | -0.19 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 |
| Reserves | -34 | -49 | -57 | -65 |
| Total liabilities | 7 | 2 | 3 | 3 |
| Fixed assets | 0 | 0 | 0 | 0 |
| Total assets | 1 | 1 | 5 | 6 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | -2 | -7 | -6 | -6 |
| Cash from investing | -0 | -0 | -0 | -0 |
| Cash from financing | 2 | 7 | 10 | 8 |
| Net cash flow | -0 | -0 | 4 | 1 |
| Capital expenditure | -0 | -0 | -0 | -0 |
| Free cash flow | -2 | -7 | -6 | -6 |
Insider filings
24 filings between Dec 23, 2025 and Oct 8, 2026.
Open market
decisions to buy or sellPurchases
$1.43M
9 purchases by 5 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 15
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Aharon Gil | $1.01M | — | Dec 23, 2025 |
| Hannasch Brian | $382.8K | — | Feb 12, 2026 |
| Henrichs Timothy Robert | $24.3K | — | Oct 8, 2026 |
| Carrico Brian Allen | $17.1K | — | Oct 8, 2026 |
| Carrico Thomas Joeseph | $2.9K | — | Oct 8, 2026 |
Latest filings (32)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 8, 2026 | Carrico Brian Allen Chief Executive Officer | Purchase | 268 | $1.3K |
| Oct 8, 2026 | Carrico Thomas Joeseph CRO, CCO, CPO | Purchase | 328 | $1.6K |
| Oct 8, 2026 | Henrichs Timothy Robert Chief Financial Officer | Purchase | 1,937 | $9.4K |
| Aug 24, 2026 | Carrico Brian Allen Chief Executive Officer | Award | 199,188 | — |
| Aug 24, 2026 | Carrico Thomas Joeseph CRO, CCO, CPO | Award | 193,678 | — |
| Aug 24, 2026 | Miranda Adrian CMO, SVP Science & Tech | Award | 199,106 | — |
| Aug 13, 2026 | Aharon Gil Director | Award | 43,930 | $275.9K |
| Aug 13, 2026 | Keyser Jane Elizabeth Director | Award | 26,073 | $163.7K |
| Aug 13, 2026 | Watkins Bradley Mitchell Director | Award | 26,073 | $163.7K |
| Aug 13, 2026 | Ferge Kristin A Director | Award | 31,134 | $195.5K |
| Jul 29, 2026 | Aharon Gil Director | Award | 2,226 | — |
| Jul 29, 2026 | Aharon Gil Director | Award | 40,068 | — |
| Apr 28, 2026 | Aharon Gil Director | Award | 221,917 | — |
| Apr 28, 2026 | Aharon Gil Director | Award | 12,304 | — |
| Apr 1, 2026 | Carrico Thomas Joeseph CRO, CCO, CPO | Purchase | 667 | $1.3K |
| Apr 1, 2026 | Henrichs Timothy Robert Chief Financial Officer | Purchase | 7,593 | $14.9K |
| Apr 1, 2026 | Carrico Brian Allen Chief Executive Officer | Purchase | 8,060 | $15.8K |
| Feb 12, 2026 | Hannasch Brian 10% owner | Purchase | 40,000 | $196.8K |
| Feb 11, 2026 | Hannasch Brian 10% owner | Purchase | 40,000 | $186.0K |
| Jan 22, 2026 | Watkins Bradley Mitchell Director | Award | 21,598 | $100.0K |
| Jan 22, 2026 | Keyser Jane Elizabeth Director | Award | 21,598 | $100.0K |
| Jan 22, 2026 | Aharon Gil Director | Award | 21,598 | $100.0K |
| Jan 22, 2026 | Ferge Kristin A Director | Award | 21,598 | $100.0K |
| Dec 23, 2025 | Aharon Gil Director | Purchase | 286,138 | $1.01M |
| Jul 1, 2025 | MASIMO CORP 10% owner | Sale | 531,548 | $1.20M |
| Jul 1, 2025 | MASIMO CORP 10% owner | Conversion | 289,779 | $29 |
| Jul 1, 2025 | MASIMO CORP 10% owner | Sale | 289,779 | $652.0K |
| Jul 1, 2025 | Hannasch Brian 10% owner | Purchase | 355,556 | $800.0K |
| Apr 21, 2025 | Hannasch Brian 10% owner | Purchase | 18,065 | $31.3K |
| Jan 17, 2025 | Keyser Jane Elizabeth Director | Award | 13,157 | $37.5K |
| Jan 17, 2025 | Ferge Kristin A Director | Award | 13,157 | $37.5K |
| Jan 17, 2025 | Watkins Bradley Mitchell Director | Award | 13,157 | $37.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Neuraxis, INC
Free account. Everything above stays public.
Write why you follow Neuraxis, INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading